The AIM All Share has had another rough day, underperforming London index peers despite the prospect of further US$ gains in the months ahead. The junior index was trading down just a fraction of a point at 719.78 by 3.30pm.
- ImmuPharma +192%
- Poolbeg Pharma +18%
- Xeros Technology +13%
- RBG Holdings -24%
- Coro Energy -22%
ImmuPharma LON:IMM is surging as we approach the close with investors cheering this morning’s news of breakthrough findings into autoimmune diseases. There’s little additional detail in the release but this does take the stock back to levels not seen in almost two and a half years.
- Three Quick Facts: Norman Broadbent, Computacenter, Immupharma
- Small Cap Stocks: Immupharm, Ondine Biomedical, Beacon Energy
Poolbeg Pharma LON:POLB added a further 18% today. The company is eyeing a merger with a Nasdaq listed entity and this morning saw the publication of stake building news.
- UK Stock Market News: Sainsbury, Clarkson, Poolbeg
- AIM Market Roundup: Team Internet, Verici, Poolbeg Pharma
Xeros Technology LON:XSG gets the notable mention, up 13%. There was a stake building notification released mid-session but volumes are limited and the spread accounts for most of the gain.
RBG Holdings LON:RBGP was the worst performer, with the stock extending Wednesday’s losses of the back of that contract dispute news. There’s arguably more to come here.
Coro Energy LON:CORO was the second worst performer at copy time, down 22%. That’s off the back of a series of corporate updates including news of a cap reognaisation and that the company was planning a fund raise of £2m. The discount here reflects the diluation from the expanded capital base.
